Concussion-sensing device receives FDA market approval

William Doss | | Radiology Business | Policy & Regulations

A wearable device that senses electronic brain activity and diagnoses brain damage received clearance from the U.S. Food and Drug Administration, allowing BrainScope to market the product commercially.

The Maryland-based company is backed by AOL founder Steve Case and receives funding from entities as varied as the Department of Defense and the National Football League.

The device has electrodes to measure brain activity and sends information to a specially configured Android phone. This is Brainscope's third device to gain FDA approval. (The previous two were for non-commercial use.)

Follow the link below to read more about BrainScope at the Star Tribune:

FDA clears wearable device to measure concussions

William Doss

As a Senior Writer for TriMed Media Group, Will covers radiology practice improvement, policy, and finance. He lives in Chicago and holds a bachelor’s degree in Life Science Communication and Global Health from the University of Wisconsin-Madison. He previously worked as a media specialist for the UW School of Medicine and Public Health. Outside of work you might see him at one of the many live music venues in Chicago or walking his dog Holly around Lakeview.

Related Content

Doc offices more than double use of nonphysicians for interpreting medical images
Radiology at a crossroads: Hopes and concerns for a second Trump administration
Massachusetts governor signs bill to expand coverage for breast imaging services
Renewed optimism that radiologist-supported bill to ease prior authorization could pass by year’s end
AMA delegates voice concern about radiologists' exposure to ionizing radiation
Radiologists and other physicians want greater scrutiny around hospitals’ nonprofit status

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
GE HealthCare moves PET/CT scanner production to United States

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.

Design by Adaptive Theme
Trimed Popup
Trimed Popup